News

July 22, 2019August 26, 2019

MSN Labs to Launch Generic Version of Zytiga in U.S. Following FDA Approval

News

MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of Janssen Pharmaceuticals’ approved therapy Zytiga (abiraterone acetate) in the U.S. market. Following its approval by the ... Read more

July 18, 2019

Liquid Biopsy Could Help Identify Aggressive Prostate Cancers, Study Says

News

A non-invasive test that examines microRNAs — small RNA molecules — in urine may be used to identify aggressive prostate cancers with great accuracy, potentially avoiding unnecessary treatments for slow-growing ... Read more

July 17, 2019

TRC253 Showing Effectiveness in Metastatic Castration-resistant Prostate Cancer Patients

News

The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the first part of a Phase ... Read more

July 15, 2019

Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show

News

A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in ... Read more

July 11, 2019

Advantagene Reaches Enrollment Goal in Phase 2 Trial Testing Prostate Cancer Vaccine

News

Advantagene, also known as Candel Therapeutics, has reached its patient enrollment goal in an ongoing Phase 2 trial testing the effectiveness of ProstAtak, the company’s prostate cancer vaccine, among men ... Read more

July 10, 2019

Liquid Biopsy Assay Being Utilized in Zejula Trials for PC

News

A liquid biopsy assay called Resolution HRD is being used in Phase 2 and Phase 3 trials of Zejula (niraparib) to help screen key mutations in prostate cancer patients. Through ... Read more

July 8, 2019

68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows

News

Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin ... Read more

July 3, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

News

Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, ... Read more

July 1, 2019

Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe

News

The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. The ... Read more

June 27, 2019June 27, 2019

Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test

News

Nanostics has started a pivotal clinical study in Canada to validate ClarityDX Prostate, a new blood test for the early diagnosis of prostate cancer. The company says the diagnostic tool ... Read more